Portfolio
Clinical Materials · Human UMSC-derived

ExoCell

Lyophilized exosome material from umbilical Wharton’s-Jelly MSCs, produced from early-passage cells and supported by full characterization for technical review.

  • UMSC-derived exosomes, early-passage source
  • Ethically sourced with donor consent and traceable oversight
  • Lyophilized for stability and transport
  • Identity, purity, sterility, and phenotype testing
ExoCell
ExoCell · Human UMSC-derived
01SpecificationsThe full spec sheet
Classification
Human UMSC-derived exosome material · professional use
Intended use
Research and technical evaluation
Not intended for
Human, clinical, or therapeutic use
Source material
Umbilical Wharton’s-Jelly MSCs, early passage, donor-consented
Format
5 mL, lyophilized
Characterization
NTA (size / concentration), TEM, CD9 / CD63 / CD81, sterility, endotoxin, mycoplasma
Storage & handling
Provided with product documentation
Shelf life
Stated on the Certificate of Analysis
Minimum order
On request by market
Lead time
Confirmed with each quote
02On the recordThe Certificate of Analysis

Characterized on
every batch.

The numbers a formulator, a clinic, and a lab need, on the Certificate of Analysis that ships with your order.

GainMed
CERTIFICATE OF ANALYSIS
Batch EC-2024-0417
Rev. 1 · illustrative
Characterization & release

What appears on your COA

Mean particle sizeNTA
118 nm
Pass
Particle concentrationNTA
2.1 × 10¹¹ /mL
Pass
MorphologyTEM
Cup-shaped
Pass
Identity markersCD9 / CD63 / CD81
Positive
Pass
SterilityUSP <71>
No growth
Pass
EndotoxinLAL
< 0.1 EU/mL
Pass
MycoplasmaqPCR
Not detected
Pass
Released by QARequest a real COA
03DocumentationWhat ships with each batch

Documentation
available.

Request any of the following for ExoCell. We share what applies to your market and intended use.

  • Technical dataon request
  • Characterization dataon request
  • Certificate of Analysison request
  • Quality informationon request
  • Handling guideon request

Professional use

ExoCell is supplied for use by licensed clinicians and their scientific/protocol teams. Every batch is released with full characterization on file; eligibility to purchase and availability are confirmed by market before dispatch.

04Also in the portfolioRelated materials

Request ExoCell.

Tell us your market and intended use. A specialist replies within one business day.

Request a Dossier